Quoin Pharmaceuticals Ltd. — Form 8-K
Filed October 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Quoin announced publication of a peer-reviewed paper (October 13, 2026) describing QRX003's mechanism in Netherton Syndrome, including a 21-month compassionate-use case report showing skin improvement from severe to clear with no adverse events. The company's Phase 2/3 study (CL-QRX003-004) expects recruitment completion by end of 2026 and topline data in Q2 2027; interim data from 6 participants showed 4/6 (66.7%) met primary endpoint (p=0.0087).
Why this rating
Publication and positive interim trial data support pipeline, but company is pre-revenue ($5.4M cap). Real but not transformational—modest clinical validation in orphan disease, results not yet definitive.
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.